Van Arendonk Kyle J, Austin J Christopher, Boyt Margaret A, Cooper Christopher S
Division of Pediatric Urology, Department of Urology, University of Iowa, Iowa City, Iowa 52242-1089, USA.
Urology. 2006 May;67(5):1049-53; discussion 1053-4. doi: 10.1016/j.urology.2005.11.060.
To examine the variables relative to the response of oxybutynin treatment in children with daytime urinary incontinence.
The records of patients seen for voiding problems between 1999 and 2003 were reviewed. Patients taking oxybutynin for 3 months or longer were included in the study. Patients with structural or neurologic bladder abnormalities and those taking oxybutynin at the initial visit were excluded. Age, sex, uroflowmetry findings, postvoid residual urine volume, duration and severity of symptoms before oxybutynin, urinary tract infection history, constipation, and the duration, dosage, and adverse effects of oxybutynin treatment were evaluated. Data were analyzed using Fisher's exact test for categorical variables, the two-sample t test or Wilcoxon rank-sum test for continuous and ordinal variables, and the linear mixed model analysis for uroflow data.
Eighty-one patients met the inclusion criteria. After an average follow-up of 1.2 years, 31 (38.3%) were dry, 25 (30.9%) had experienced significant improvement, 19 (23.5%) had experienced slight improvement, and 6 (7.4%) were unchanged. No significant differences were detected between those who became dry and those with little to no improvement with respect to age, sex, duration of symptoms, follow-up, uroflow pattern, postvoid residual urine volume, or bladder capacity. Those children presenting with decreased frequency of wetting episodes were significantly more likely to obtain daytime continence. The most common side effects were constipation (18.5%), dry mouth (17.3%), and flushing (13.6%).
Children with daytime incontinence presenting with the lowest frequency of wetting were most likely to achieve continence. The frequency of wetting should be considered a significant prognostic variable when assessing the results of therapeutic intervention trials.
研究与奥昔布宁治疗小儿日间尿失禁反应相关的变量。
回顾1999年至2003年间因排尿问题就诊患者的记录。纳入服用奥昔布宁3个月或更长时间的患者。排除有结构性或神经性膀胱异常的患者以及初诊时服用奥昔布宁的患者。评估年龄、性别、尿流率检查结果、排尿后残余尿量、服用奥昔布宁前症状的持续时间和严重程度、尿路感染史、便秘情况以及奥昔布宁治疗的持续时间、剂量和不良反应。使用Fisher精确检验分析分类变量,使用两样本t检验或Wilcoxon秩和检验分析连续变量和有序变量,并使用线性混合模型分析尿流数据。
81例患者符合纳入标准。平均随访1.2年后,31例(38.3%)已无遗尿,25例(30.9%)有显著改善,19例(23.5%)有轻微改善,6例(7.4%)无变化。在已无遗尿的患者与几乎没有改善或无改善的患者之间,在年龄、性别、症状持续时间、随访、尿流模式、排尿后残余尿量或膀胱容量方面未检测到显著差异。遗尿发作频率降低的儿童更有可能实现日间控尿。最常见的副作用是便秘(18.5%)、口干(17.3%)和脸红(13.6%)。
日间尿失禁且遗尿频率最低的儿童最有可能实现控尿。在评估治疗干预试验结果时,遗尿频率应被视为一个重要的预后变量。